PMGC Holdings Inc.'s (NASDAQ:ELAB) ("PMGC," "we," or "our") wholly owned subsidiary, NorthStrive Biosciences Inc. ("Northstrive Biosciences"), announced today a third amendment ("Amendment") to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company ("MOA," and such existing agreement, as amended, "License Agreement") Northstrive Biosciences holds for EL-32 and EL-22.

The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties' research and development and regulatory expectations.

Northstrive Biosciences believes the Amendment reinforces the company's commitment to disciplined development planning and the continued progression of its human health portfolio.

About MOA Life Plus Co. Ltd. [KOSDAQ: 142760]

MOA Life Plus Co. Ltd.is a Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies. MOA partners globally to advance scientific innovation across human and animal health applications.